On November 16, Quantinuum fell 5.76% in Regular Trading, trading at $33.625 per share, with turnover of $10.71 million.
The clearest catalyst in public news flow was continued pressure from multiple post-earnings analyst target cuts, which kept weighing on valuation expectations despite broadly constructive ratings.
After its November 5 quarterly update, Quantinuum reported third-quarter revenue of $9.1 million, above consensus near $8.1 million, and raised full-year revenue guidance to $31 million-$34 million from $28 million-$32 million. Even so, several firms reduced price targets, including UBS to $50 from $93, while Mizuho, Needham, and Jefferies lowered theirs to $70, $60, and $65, respectively. The combination suggests investors are still reassessing commercialization timing and valuation levels after earnings.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments